Evidence map›Paper›PMID 40208558›Full record

ArticleDermatology and therapy2025

Demographics and Clinical Characteristics among Patients with Distinct Psychosocial Burden Profiles Related to Vitiligo: Results of a Latent Class Analysis.

Kent A Hanson, Khaled Ezzedine, Jenny Austin, Peter Anderson, Simran Marwaha, Samantha K Kurosky, Roni Adiri, James Piercy, Ernest H Law

Abstract read
In one paragraph

Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kent A HansonPfizer Inc, New York, NY, USA.ORCID http://orcid.org/0000-0002-7201-3324
Khaled EzzedineDepartment of Dermatology, AP-HP, Henri Mondor University Hospital, UPEC, Créteil, France.ORCID http://orcid.org/0000-0002-5468-4589
Jenny AustinAdelphi Real World, Bollington, UK.ORCID http://orcid.org/0000-0003-4297-6290
Peter AndersonAdelphi Real World, Bollington, UK.ORCID http://orcid.org/0000-0002-2171-8228
Simran MarwahaAdelphi Real World, Bollington, UK.ORCID http://orcid.org/0000-0003-0380-0372
Samantha K KuroskyPfizer Inc, New York, NY, USA.ORCID http://orcid.org/0000-0003-2392-8111
Roni AdiriPfizer Pharmaceuticals Israel Ltd., Herzliya Pituach, Israel.ORCID http://orcid.org/0009-0008-8944-8421
James PiercyAdelphi Real World, Bollington, UK.ORCID http://orcid.org/0000-0001-7015-1021
Ernest H LawPfizer Inc, New York, NY, USA. ernest.law@pfizer.com.ORCID http://orcid.org/0000-0002-6111-8008

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVitiligo may negatively impact quality of life (QOL). This study aimed to classify patients on the basis of the impact of vitiligo on emotional/psychological and social functioning and describe patient characteristics and patient-reported outcome (PRO) responses for each profile.

methodsPhysician and patient surveys from the Vitiligo Disease Specific Programme in France, Germany, Italy, Spain, and the USA were analyzed. PROs were assessed using the Vitiligo Patient Priority Outcomes (ViPPO), Work Productivity Activity Index-Vitiligo, Vitiligo-Specific Quality-of-Life instrument, 5-level EuroQol 5-dimensional questionnaire (EQ-5D-5L), and Hospital Anxiety and Depression Scale questionnaires. Latent class analysis identified distinct classes on the basis of ViPPO response options.

resultsA three-class model was selected. Of 530 patients, 64.2%, 24.3%, and 11.5% were grouped into classes 1, 2, and 3, respectively. Class 3 reported the most emotional/psychological and social functioning impact; classes 1 and 2 reported mild and moderate impact, respectively. More patients in classes 1 and 2 had moderate physician-assessed disease; class 3 had a higher proportion of patients with moderate-to-severe disease; however, approximately one third had limited/mild physician-reported disease. Class 3 had the highest mean body surface area involvement and proportion of patients with face involvement (n = 30 [49.2%]). Across all 4 PRO measures, class 3 reported more severe impacts.

conclusionsGenerally, classes with more severe impacts had more severe physician-assessed disease and lesion involvement and greater work productivity and QOL impairment. Although patients in class 3 had severe psychosocial burden, a large proportion had mild physician-reported disease severity, suggesting that only physical symptoms were considered when assessing disease severity.

Indexed as

Latent class analysisPatient-reported outcomesPsychosocial burdenVitiligo

Identifiers

PMID40208558
PMCPMC12033137

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.